Pathophysiology of stroke-like episodes in MELAS: Neuron-astrocyte uncoupling in neuronal hyperexcitability

Future Neurology

Volumn 5, Issue 1, 2010, Pages 61-83

  Iizuka, Takahiro ^a   Sakai, Fumihiko ^b  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b International Headache Center   (Japan)

Author keywords

Headache; MELAS; Mitochondrial angiopathy; Neuron astrocyte communications; Neuronal hyperexcitability; Reactive oxygen species; Seizure; Stroke like episodes

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); AMPA RECEPTOR; ARGININE; CALCITONIN GENE RELATED PEPTIDE; CITRULLINE; DNA DIRECTED DNA POLYMERASE GAMMA; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GADOLINIUM; GELATINASE B; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; GLUTAMIC ACID; INTERLEUKIN 6; METABOTROPIC RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE; NITRIC OXIDE; NORPHENAZONE; PHENYTOIN; PROSTAGLANDIN SYNTHASE; PROTEIN S100B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SUMATRIPTAN;

BRAIN EDEMA; BRAIN PERFUSION; CALCIUM SIGNALING; CEREBROSPINAL FLUID ANALYSIS; CEREBROVASCULAR ACCIDENT; DISEASE COURSE; ELECTROENCEPHALOGRAM; ENDOTHELIAL DYSFUNCTION; EPILEPTIC DISCHARGE; EPILEPTOGENESIS; HEADACHE; HEMIPARESIS; HETEROZYGOSITY; HUMAN; LEBER HEREDITARY OPTIC NEUROPATHY; MELAS SYNDROME; MERRF SYNDROME; MIGRAINE; MISSENSE MUTATION; NERVE EXCITABILITY; NEUROIMAGING; NEUROMODULATION; NEUROPATHOLOGY; NOCICEPTION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEIZURE; SYNAPTIC TRANSMISSION; TRIGEMINAL NERVE; VISUAL FIELD DEFECT; VISUAL HALLUCINATION;

EID: 77949433548     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/fnl.09.71     Document Type: Review

References (103)

1. Pavlakis SG, Phillips PC, Dimauro S, De Vivo DC, Rowland LP: Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes: a distinctive clinical syndrome. Ann.Neurol. 16(4), 481-488 (1984).
2. Martínez-Fernández E, Gil-Peralta A, García-Lozano R et al.: Mitochondrial disease and stroke. Stroke 32(11), 2507-2510 (2001).
3. Longo N, Schrijver I, Vogel H et al.: Progressive cerebral vascular degeneration with mitochondrial encephalopathy. Am.J. Med. Genet. A 146(3), 361-367 (2008).
4. Finsterer J: Management of mitochondrial stroke-like-episodes. Eur.J. Neurol. 16(11), 1178-1184 (2009).
5. Iizuka T, Sakai F: Pathogenesis of stroke-like episodes in MELAS: analysis of neurovascular cellular mechanisms. Curr.Neurovasc. Res. 2(1), 29-45 (2005).
6. Iizuka T, Sakai F, Suzuki N et al.: Neuronal hyperexcitability in stroke-like episodes of MELAS syndrome. Neurology 59(6), 816-824 (2002).
7. Iizuka T, Sakai F, Kan S, Suzuki N: Slowly progressive spread of the stroke-like lesions in MELAS. Neurology 61(9), 1238-1244 (2003).
8. Iizuka T, Sakai F, Ide T, Miyakawa S, Sato M, Yoshii S: Regional cerebral blood flow and cerebrovascular reactivity during chronic stage of stroke-like episodes in MELAS - implication of neurovascular cellular mechanism. J.Neurol. Sci. 257(1-2), 126-138 (2007).
9. Koga Y, Akita Y, Junko N et al.: Endothelial dysfunction in MELAS improved by l-arginine supplementation. Neurology 66(11), 1766-1769 (2006).
10. Koga Y, Akita Y, Nishioka J et al.: MELAS and l-arginine therapy. Mitochondrion 7(1-2), 133-139 (2007).
11. Naini A, Kaufmann P, Shanske S, Engelstad K, De Vivo DC, Schon EA: Hypocitrullinemia in patients with MELAS: an insight into the "MELAS paradox". J.Neurol. Sci. 229-230, 187-193 (2005).
12. Sproule DM, Kaufmann P: Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes: basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome. Ann. NY Acad. Sci. 1142, 133-158 (2008).
13. Ikawa M, Okazawa H, Arakawa K et al.: PET imaging of redox and energy states in stroke-like episodes of MELAS. Mitochondrion 9(2), 144-148 (2009).
14. Benarroch EE: Neuron-astrocyte interactions: partnership for normal function and disease in the central nervous system. MayoClin. Proc. 80(10), 1326-1338 (2005).
15. Haydon PG, Carmignoto G: Astrocyte control of synaptic transmission and neurovascular coupling. Physiol.Rev. 86(3), 1009-1031 (2006).
16. Fellin T: Communication between neurons and astrocytes: relevance to the modulation of synaptic and network activity. J. Neurochemistry108, 533-544 (2009).
17. Koehler RC, Roman RJ, Harder DR: Astrocytes and the regulation of cerebral blood flow. TrendsNeurosci. 32(3), 160-169 (2009).
18. Iizuka T, Miyakawa S, Sato M, Yabuki Y, Hamada J, Sakai S: Neuronal hyperexcitability and trigeminovascular activation during acute stage of stroke-like episodes in MELAS. Neurology 70(Suppl. 1), A49 (2008).
19. Kirino Y, Suzuki T: Human mitochondrial diseases associated with tRNA wobble modification deficiency. RNA Biol. 2(2), 41-44 (2005).
20. Hirano M, Ricci E, Koenigsberger MR et al.: MELAS: an original case and clinical criteria for diagnosis. Neuromuscul. Disord. 2(2), 125-135 (1992).
21. Iizuka T, Sakai F, Endo M, Suzuki N: Response to sumatriptan in headache of MELAS syndrome. Neurology 61(4), 577-578 (2003).
22. Benemei S, Nicoletti P, Capone JG, Geppetti P: CGRP receptors in the control of pain and inflammation. Curr.Opin. Pharmacol. 9(1), 9-14 (2009).
23. Gursoy-Ozdemir Y, Qiu J, Matsuoka N et al.: Cortical spreading depression activates and upregulates MMP-9. J.Clin. Invest. 113(10), 1447-1455 (2004).
24. Yushchenko M, Weber F, Mäder M et al.: Matrix metalloproteinase-9 (MMP-9) in human cerebrospinal fluid (CSF): elevated levels are primarily related to CSF cell count. J. Neuroimmunol. 110(1-2), 244-251 (2000).
25. Feddersen B, Bender A, Arnold S, Klopstock T, Noachtar S: Aggressive confusional state as a clinical manifestation of status epilepticus in MELAS. Neurology 61(8), 1149-1150 (2003).
26. Corda D, Rosati G, Deiana GA, Sechi G: "Erratic" complex partial status epilepticus as a presenting feature of MELAS. Epilepsy Behav. 8(3), 655-658 (2006).
27. Alberti A, Paciaroni M, Caso V, Venti M, Palmerini F, Agnelli G: Early seizures in patients with acute stroke: frequency, predictive factors, and effect on clinical outcome. Vasc. Health Risk Manag. 4(3), 715-720 (2008).
28. Bladin CF, Alexandrov AV, Bellavance A et al.: Seizures after stroke: a prospective multicenter study. Arch. Neurol. 57(11), 1617-1622 (2000).
29. Hirano M, Pavlakis SG: Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke like episodes (MELAS): current concepts. J.Child Neurol. 9(1), 4-13 (1994).
30. Goto Y, Horai S, Matsuoka T et al.: Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): a correlative study of the clinical features and mitochondrial DNA mutation. Neurology 42(3-1), 545-550 (1992).
31. Yoneda M, Maeda M, Kimura H, Fujii A, Katayama K, Kuriyama M: Vasogenic edema on MELAS: a serial study with diffusionweighted MR imaging. Neurology 53(9), 2182-2184 (1999).
32. Yonemura K, Hasegawa Y, Kimura K, Minematsu K, Yamaguchi T: Diffusionweighted MR imaging in a case of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke like episodes. AJNR 22(2), 269-272 (2001).
33. Kolb SJ, Costello F, Lee AG et al.: Distinguishing ischemic stroke from the stroke-like lesions of MELAS using apparent diffusion coefficient mapping. J.Neurol. Sci. 216(1), 11-15 (2003).
34. Ito H, Mori K, Harada M et al.: Serial brain imaging analysis of stroke-like episodes in MELAS. Brain Dev. 30(7), 483-488 (2008).
35. Tzoulis C, Bindoff LA: Serial diffusion imaging in a case of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes. Stroke 40(2), E15-E17 (2009).
36. Takahashi S, Tohgi H, Yonezawa H, Obara S, Nagane Y: Cerebral blood flow and oxygen metabolism before and after a stroke-like episode in patients with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). J.Neurol. Sci. 158(1), 58-64 (1998).
37. Nariai T, Ohno K, Akimoto H et al.: Cerebral blood flow, vascular response and metabolism in patients with MELAS syndrome - xenon CT and PET study. Keio J. Med. 49(Suppl. 1), A68-A70 (2000).
38. Kaufmann P, Shungu DC, Sano MC et al.: Cerebral lactic acidosis correlates with neurological impairment in MELAS. Neurology 62(8), 1297-1302 (2004).
39. Yokoyama T, Hasegawa K, Obama R, Ishihara T, Yagishita S: MELAS with diffuse degeneration of the cerebral white matter: report of an autopsy case. Neuropathology DOI: 10.1111/j.1440-1789.2009.01026.x (2009) (Epub ahead of print).
40. Betts J, Jaros E, Perry RH et al.: Molecular neuropathology of MELAS: level of heteroplasmy in individual neurons and evidence of extensive vascular involvement. Neuropathol. Appl. Neurobiol. 32(4), 359-373 (2006).
41. Filosto M, Tomelleri G, Tonin P et al.: Neuropathology of mitochondrial diseases. Biosci. Rep. 27(1-3), 23-30 (2007).
42. Ohama E, Ohara S, Ikuta F, Tanaka K, Nishizawa M, Miyatake T: Mitochondrial angiopathy in cerebral blood vessels of mitochondrial encephalomyopathy. Acta Neuropathol. 74(3), 226-233 (1987).
43. Sakuta R, Nonaka I: Vascular involvement in mitochondrial myopathy. Ann. Neurol. 25(6), 594-601 (1989).
44. Ohama E, Ikuta F.: Involvement of choroid plexus in mitochondrial encephalomyopathy (MELAS). Acta Neuropathol. 75(1), 1-7 (1987).
45. Sparaco M, Simonati A, Cavallaro T et al.: MELAS: clinical phenotype and morphological brain abnormalities. Acta Neuropathol. 106, 202-212 (2003).
46. Koga Y, Ishibashi M, Ueki I et al.: Effects of l-arginine on the acute phase of strokes in three patients with MELAS. Neurology 58 (5), 827-828 (2002).
47. Koga Y, Akita Y, Nishioka J et al.: l-arginine improves the symptoms of strokelike episodes in MELAS. Neurology 64(4), 710-712 (2005).
48. Petruzzella V, Moraes CT, Sano MC, Bonilla E, DiMauro S, Schon EA: Extremely high levels of mutant mtDNAs co-localize with cytochrome c oxidase-negative ragged-red fibers in patients harboring a point mutation at nt-3243. Hum. Mol. Genet. 3(3), 449-454 (1994).
49. Hirata K, Akita Y, Povalko N et al.: Effect of l-arginine on synaptosomal mitochondrial function. Brain Dev. 30(4), 238-245 (2008).
50. Pellerin L, Magistretti PJ: Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc.Natl Acad. Sci. USA 91(22), 10625-10629 (1994).
51. Kasischke KA, Vishwasrao HD, Fisher PJ, Zipfel WR, Webb WW: Neural activity triggers neuronal oxidative metabolism followed by astrocytic glycolysis. Science 305(5680), 99-103 (2004).
52. Pellerin L, Bouzier-Sore AK, Aubert A et al.: Activity-dependent regulation of energy metabolism by astrocytes: an update. Glia 55(12), 1251-1262 (2007).
53. Maekawa F, Tsuboi T, Pellerin L: Regulation of the intracellular distribution, cell surface expression, and protein levels of AMPA receptor GluR2 subunits by the monocarboxylate transporter MCT2 in neuronal cells. J. Neurochem. 109(6), 1767-1778 (2009).
54. Takano T, Tian GF, Peng W et al.: Astrocyte-mediated control of cerebral blood flow. Nat. Neurosci. 9(2), 260-267 (2006).
55. Mulligan SJ, MacVicar BA: Calcium transients in astrocyte endfeet cause cerebrovascular constrictions. Nature 431(7005), 195-199 (2004).
56. Gordon GR, Choi HB, Rungta RL, Ellis-Davies GC, MacVicar BA: Brain metabolism dictates the polarity of astrocyte control over arterioles. Nature 456, 745-750 (2008).
57. Iadecola C, Nedergaard M: Glial regulation of the cerebral microvasculature. Nat. Neurosci. 10(11), 1369-1376 (2007).
58. Boison D: The adenosine kinase hypothesis of epileptogenesis. Prog. Neurobiol. 84(3), 249-262 (2008).
59. Indo HP, Davidson M, Yen HC et al.: Evidence of ROS generation by mitochondria in cells with impaired electron transport chain and mitochondrial DNA damage. Mitochondrion 7(1-2), 106-118 (2007).
60. Chrissobolis S, Faraci FM: The role of oxidative stress and NADPH oxidase in cerebrovascular disease. Trends Mol. Med. 14(11), 495-502 (2008).
61. Davidson MM, Walker WF, Hernandez-Rosa E: The m.3243A>G mtDNA mutation is pathogenic in an invitro model of the human blood brain barrier. Mitochondrion 9(6), 463-470 (2009).
62. Tanaka M, Nishigaki Y, Fuku N, Ibi T, Sahashi K, Koga Y: Therapeutic potential of pyruvate therapy for mitochondrial diseases. Mitochondrion 7(6), 399-401 (2007).
63. Tian GF, Azmi H, Takano T et al.: An astrocytic basis of epilepsy. Nat.Med. 11(9), 973-981 (2005).
64. Liang SL, Carlson GC, Coulter DA: Dynamic regulation of synaptic GABA release by the glutamate-glutamine cycle in hippocampal area CA1. J. Neurosci. 26(33), 8537-8548 (2006).
65. Moskowitz MA, Bolay H, Dalkara T: Deciphering migraine mechanisms: clues from familial hemiplegic migraine genotypes. Ann. Neurol. 55(2), 276-280 (2004).
66. Difrancesco JC, Cooper JM, Lam A et al.: MELAS mitochondrial DNA mutation A3243G reduces glutamate transport in cybrids cell lines. Exp.Neurol. 212(1), 152-156 (2008).
67. Hanna MG, Nelson IP, Morgan-Hughes JA, Wood NW: MELAS: a new disease associated mitochondrial DNA mutation and evidence for further genetic heterogeneity. J. Neurol. Neurosurg. Psychiatry 65(4), 512-517 (1998).
68. Iizuka T, Goto Y, Miyakawa S et al.: Progressive carotid artery stenosis with a novel tRNA phenylalanine mitochondrial DNA mutation. J. Neurol. Sci. 278(1-2), 35-40 (2009).
69. Taylor RW, Chinnery PF, Haldane F et al.: MELAS associated with a mutation in the valine transfer RNA gene of mitochondrial DNA. Ann. Neurol. 40(3), 459-462 (1996).
70. Menotti F, Brega A, Diegoli M, Grasso M, Modena MG, Arbustini E: A novel mtDNA point mutation in tRNA(Val) is associated with hypertrophic cardiomyopathy and MELAS. Ital. Heart J. 5(6), 460-465 (2004)
71. Shaag A, Saada A, Steinberg A, Navon P, Elpeleg ON: Mitochondrial encephalomyopathy associated with a novel mutation in the mitochondrial tRNALeu(UUR) gene (A3243T). Biochem. Biophys. Res. Commun. 233(3), 637-639 (1997).
72. Leu(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 348(6302), 651-653 (1990).
73. Mimaki M, Hatakeyama H, Ichiyama T et al.: Different effects of novel mtDNA G3242A and G3244A base changes adjacent to a common A3243G mutation in patients with mitochondrial disorders. Mitochondrion. 9(2) 115-122 (2009).
74. Morten KJ, Cooper JM, Brown GK, Lake BD, Pike D, Poulton J: A new point mutation associated with mitochondrial encephalomyopathy. Hum. Mol. Genet. 2(12), 2081-2087 (1993).
75. ALeu(UUR) mutation at 3,256 associated with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). Biochem. Mol. Biol. Intern. 33(6), 1055-1061 (1994).
76. Nishino I, Komatsu M, Kodama S, Horai S, Nonaka I, Goto Y: The 3260 mutation in mitochondrial DNA can cause mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS). Muscle Nerve 19(12), 1603-1604 (1996).
77. Goto Y, Nonaka I, Horai S: A new mtDNA mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Biochim. Biophys. Acta 1097(3), 238-240 (1991).
78. Goto Y, Tsugane K, Tanabe Y, Nonaka I, Horai S: A new point mutation at nucleotide pair 3291 of the mitochondrial tRNALeu(UUR) gene in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). Biochem. Biophys. Res. Commun. 202(3), 1624-1630 (1994).
79. Campos Y, Martín MA, Rubio JC, Gutiérrez del Olmo MC, Cabello A, Arenas J: Bilateral striatal necrosis and MELAS associated with a new T3308C mutation in the mitochondrial ND1 gene. Biochem. Biophys. Res. Commun. 238(2), 323-325 (1997).
80. Blakely EL, de Silva R, King A et al.: LHON/MELAS overlap syndrome associated with a mitochondrial MTND1 gene mutation. Eur. J. Hum. Genet. 13(5), 623-627 (2005).
81. Horváth R, Reilmann R, Holinski-Feder E, Ringelstein EB, Klopstock T: The role of complex I genes in MELAS: a novel heteroplasmic mutation 3380G>A in ND1 of mtDNA. Neuromuscul. Disord. 18 (7), 553-556 (2008).
82. Kirby DM, McFarland R, Ohtake A et al.: Mutations of the mitochondrial ND1 gene as a cause of MELAS. J.Med. Genet. 41(10), 784-789 (2004).
83. Bataillard M, Chatzoglou E, Rumbach L et al.: Atypical MELAS syndrome associated with a new mitochondrial tRNA glutamine point mutation. Neurology 56(3), 405-407 (2001).
84. Tam EW, Feigenbaum A, Addis JB et al.: A novel mitochondrial DNA mutation in COX1 leads to strokes, seizures, and lactic acidosis. Neuropediatrics 39(6), 328-334 (2008).
85. Nakamura M, Nakano S, Goto Y et al.: A novel point mutation in the mitochondrial tRNASer(UCN) gene detected in a family with MERRF/MELAS overlap syndrome. Biochem. Biophys. Res. Commun. 214(1), 86-93 (1995).
86. Rossmanith W, Freilinger M, Roka J et al.: Isolated cytochrome c oxidase deficiency as a cause of MELAS. J. Med. Genet. 45(2), 117-121 (2008).
87. Lys gene A8296G mutation. Pediatr. Neurol. 27(5), 397-400 (2002).
88. Lys gene mutation (T8316C) in a patient with mitochondrial myopathy, lactic acidosis, and stroke-like episodes. Neuromuscul. Disord. 10(7), 493-496 (2000).
89. Lys gene. Eur. J. Hum. Genet. 1(1), 80-87 (1993).
90. Manfredi G, Schon EA, Moraes CT et al.: A new mutation associated with MELAS is located in a mitochondrial DNA polypeptidecoding gene. Neuromuscul. Disord. 5(5), 391-398 (1995).
91. Werner KG, Morel CF, Kirton A et al.: Rolandic mitochondrial encephalomyelopathy and MT-ND3 mutations. Pediatr.Neurol. 41(1), 27-33 (2009).
92. Melone MA, Tessa A, Petrini S et al.: Revelation of a new mitochondrial DNA mutation (G12147A) in a MELAS/MERFF phenotype. Arch. Neurol. 61(2), 269-272 (2004).
93. Ser(AGY) gene associated with mitochondrial myopathy, encephalopathy, and complex I deficiency. J. Med. Genet. 43(9), E46 (2006).
94. Abu-Amero KK, Ozand PT, Al-Dhalaan H: Novel mitochondrial DNA transversion mutation in transfer ribonucleic acid for leucine 2 (CUN) in a patient with the clinical features of MELAS. J. Child Neurol. 21(11), 971-972 (2006).
95. Liolitsa D, Rahman S, Benton S, Carr LJ, Hanna MG: Is the mitochondrial complex I ND5 gene a hot-spot for MELAS causing mutations? Ann. Neurol. 53(1), 128-132 (2003).
96. Naini AB, Lu J, Kaufmann P et al.: Novel mitochondrial DNA ND5 mutation in a patient with clinical features of MELAS and MERRF. Arch. Neurol. 62(3), 473-476 (2005).
97. Crimi M, Galbiati S, Moroni I et al.: A missense mutation in the mitochondrial ND5 gene associated with a Leigh-MELAS overlap syndrome. Neurology 60(11), 1857-1861 (2003).
98. Santorelli FM, Tanji K, Kulikova R et al.: Identification of a novel mutation in the mtDNA ND5 gene associated with MELAS. Biochem. Biophys. Res. Commun. 238(2), 326-328 (1997).
99. Corona P, Antozzi C, Carrara F et al.: A novel mtDNA mutation in the ND5 subunit of complex I in two MELAS patients. Ann. Neurol. 49(1), 106-110 (2001).
100. McKenzie M, Liolitsa D, Akinshina N et al.: Mitochondrial ND5 gene variation associated with encephalomyopathy and mitochondrial ATP consumption. J.Biol. Chem. 282(51), 36845-36852 (2007).
101. Ravn K, Wibrand F, Hansen FJ, Horn N, Rosenberg T, Schwartz M: An mtDNA mutation, 14453G→A, in the NADH dehydrogenase subunit 6 associated with severe MELAS syndrome. Eur. J. Hum. Genet. 9(10), 805-809 (2001).
102. Deschauer M, Tennant S, Rokicka A et al.: MELAS associated with mutations in the POLG1 gene. Neurology 68(20), 1741-1742 (2007).
103. Official gene designations. www.mitomap.org/cgi-bin/tbl1gen.pl